10-Q

0001754068--12-31Q1falsehttp://fasb.org/us-gaap/2023#RelatedPartyMemberhttp://fasb.org/us-gaap/2023#RelatedPartyMember00017540682023-12-310001754068us-gaap:OverAllotmentOptionMemberalvr:JPMorganSecuritiesLlcMember2023-06-210001754068alvr:UnvestedRestrictedStockMember2024-01-012024-03-310001754068us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-03-310001754068us-gaap:RetainedEarningsMember2023-12-310001754068alvr:TwoThousandTwentyTwoStatementOfWorkUnderDevelopmentAndManufacturingServicesAgreementMember2022-10-310001754068us-gaap:RestrictedStockMember2024-01-012024-03-310001754068us-gaap:RetainedEarningsMember2023-03-3100017540682024-01-012024-03-310001754068us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-03-310001754068us-gaap:FairValueInputsLevel1Member2024-03-3100017540682024-03-310001754068alvr:USGovernmentTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Member2023-12-310001754068us-gaap:RetainedEarningsMember2024-01-012024-03-310001754068us-gaap:EmployeeStockOptionMember2024-03-310001754068us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001754068us-gaap:AdditionalPaidInCapitalMember2022-12-310001754068us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-03-310001754068alvr:OptionToPurchaseCommonStockMember2024-03-310001754068us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2023-12-310001754068us-gaap:OverAllotmentOptionMemberalvr:JPMorganSecuritiesLlcMember2023-06-212023-06-210001754068alvr:TwoThousandAndEighteenEquityIncentivePlanMember2024-03-310001754068us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001754068us-gaap:RestrictedStockMemberalvr:TwoThousandAndEighteenEquityIncentivePlanMember2024-01-012024-03-310001754068us-gaap:CommonStockMember2022-12-310001754068alvr:TwoThousandTwentyTwoStatementOfWorkUnderDevelopmentAndManufacturingServicesAgreementMember2023-12-012023-12-310001754068us-gaap:RetainedEarningsMember2024-03-310001754068us-gaap:CommonStockMember2023-03-310001754068alvr:TwoThousandAndTwentyEmployeeStockPurchasePlanMember2023-01-012023-03-310001754068alvr:TwoThousandAndTwentyEmployeeStockPurchasePlanMember2024-03-310001754068alvr:TwoThousandTwentyStockOptionAndGrantPlanMember2024-01-012024-03-310001754068us-gaap:CommonStockMember2023-01-012023-03-310001754068us-gaap:MoneyMarketFundsMember2023-12-3100017540682023-03-310001754068us-gaap:CommonStockMember2023-12-310001754068us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001754068us-gaap:RestrictedStockMember2023-01-012023-03-310001754068us-gaap:RestrictedStockMember2023-12-310001754068us-gaap:FairValueInputsLevel1Member2023-12-310001754068alvr:TwoThousandTwentyStockOptionAndGrantPlanMemberalvr:StockAvailableForGrantMember2023-12-310001754068alvr:TwoThousandAndTwentyEmployeeStockPurchasePlanMember2024-01-012024-03-310001754068us-gaap:RelatedPartyMember2023-12-310001754068us-gaap:CommonStockMember2024-03-310001754068us-gaap:AdditionalPaidInCapitalMember2023-03-310001754068us-gaap:EmployeeStockOptionMember2024-01-012024-03-310001754068alvr:WalthamLeasesMember2024-01-012024-03-310001754068alvr:ElevateBioAndAffiliatesMember2023-01-012023-03-310001754068alvr:MarkerTherapeuticsIncMember2024-03-310001754068alvr:TwoThousandTwentyStockOptionAndGrantPlanMemberalvr:StockAvailableForGrantMember2024-03-3100017540682024-01-012024-01-310001754068us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001754068alvr:StockAvailableForIssuanceMemberalvr:TwoThousandAndTwentyEmployeeStockPurchasePlanMember2024-03-310001754068alvr:StockAvailableForIssuanceMemberalvr:TwoThousandAndTwentyEmployeeStockPurchasePlanMember2023-12-3100017540682023-01-012023-03-310001754068alvr:ElevateBioAndAffiliatesMember2024-03-3100017540682023-01-012023-12-310001754068us-gaap:RetainedEarningsMember2022-12-3100017540682023-05-150001754068alvr:UnvestedRestrictedStockMember2023-01-012023-03-310001754068alvr:SubleaseWithAmagPharmaceuticalsMember2021-09-300001754068us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001754068alvr:WalthamLeasesMember2021-09-300001754068alvr:USGovernmentTreasurySecuritiesMember2024-03-310001754068alvr:OptionToPurchaseCommonStockMember2023-12-310001754068alvr:UnvestedRestrictedStockMember2023-12-310001754068us-gaap:RetainedEarningsMember2023-01-012023-03-310001754068us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001754068alvr:OptionsToPurchaseCommonStockMember2023-01-012023-03-310001754068alvr:MarkerTherapeuticsIncMember2023-12-310001754068alvr:OptionsToPurchaseCommonStockMember2024-01-012024-03-310001754068

SEC Form 10-Q filed by AlloVir Inc.